HilleVax looks to offer first ever vaccine for norovirus

12 January 2024
vaccine_shot_jab_booster_big

HilleVax (Nasdaq: HLVX) has agreed terms for a licensing deal with Chengdu-based Kanghua Biological (SHE: 300841), a Chinese biotech also known as Kangh.

The agreement covers Kangh’s hexavalent virus-like particle (VLP) norovirus vaccine candidate, known as HIL-216, outside of China, Hong Kong, Taiwan and Macau.

HilleVax will pay Kangh an upfront payment of $15 million with the potential for additional payments of up to $256 million in milestones, plus single-digit tiered royalties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology